|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Pancreatic carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Pancreatic carcinoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is particularly resistant to apoptosis by antineoplastic agents, which is partly attributable to the lack of functional p53.
|
11585734 |
2001 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53 and BRCA2 germline mutations seem not to be significantly associated with the occurrence of multiple primaries in pancreatic cancer patients.
|
11075991 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Trp53(+/-) mice overexpressing Tgfalpha in a pancreas-specific manner represent a well-established animal model for pancreatic cancer.
|
14506698 |
2003 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A combined approach targeting HDAC1/HDAC2 and MYC may present a novel and molecularly defined strategy to target mutant p53 in pancreatic cancer.
|
27721407 |
2017 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A molecular examination of Ki-ras codon 12 and p53 mutations therefore enables us to predict, to some degree, the occurrence of liver and lymph node metastasis in pancreatic carcinoma.
|
10950039 |
2000 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
|
1764370 |
1991 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Accumulating evidence strongly suggests that p53 mutations contribute to the acquisition and/or maintenance of drug-resistant property of pancreatic cancer.
|
29558908 |
2018 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation of the proto-oncogene K-Ras and inactivation of the tumour suppressor gene loci INK4a, p53 and SMAD4 are characteristic for pancreatic cancer.
|
12079267 |
2002 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated p53 gene transfer suppressed growth of all human pancreatic cancer cell lines in a dose-dependent manner.
|
9869513 |
1998 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Advances in the understanding of pancreas cancer biology have been made over the past decade, including the discovery of critical mutations in oncogenes (i.e., K-Ras) as well as the loss of tumor suppressor genes, such as TP53 and p16(INK4).
|
16818496 |
2006 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer.
|
7947080 |
1994 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Analysis by scanning electron microscopy revealed that these supernumerary structures are devoid of centrioles, a result significantly different from observations in aneuploid pancreatic cancer cell lines and in Trp53 or Brca1 deficient MEFs.
|
19768832 |
2009 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice.
|
26411367 |
2016 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Archival cytology samples obtained from 17 patients with established pancreatic carcinoma were assayed for alterations in K-ras and p53.
|
7730480 |
1995 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Based on these findings, trichodermin is a potential therapeutic agent worthy of further development into a clinical trial candidate for treating cancer, especially the mutant p53 pancreatic cancer.
|
27965041 |
2017 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Both failed to specifically suppress p53 protein production in a cell-free assay system or to have any effect on mutant p53 expression by human pancreatic cancer cell lines.
|
7880719 |
1995 |
|
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Both genetic analysis and IP are required to characterize all p53 mutations in pancreatic cancer.
|
8927612 |
1996 |
|
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be important in pancreatic cancer (TP53, SMAD4, CDKN2A, ARID1A and ROBO2) and new candidate drivers of pancreatic carcinogenesis (KDM6A and PREX2).
|
25719666 |
2015 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
|
16127777 |
2005 |
|
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
|
12171884 |
2002 |